News Release

There’s an uptick in pricing by anesthesiologists: What role do management companies play?

Peer-Reviewed Publication

Columbia University's Mailman School of Public Health

Prices paid to anesthesia practitioners increased after hospital outpatient departments and ambulatory surgery centers contracted with a physician management company (PMC), and were substantially higher if the PMC received private equity (PE) investment, according to a study by researchers at Columbia University Mailman School of Public Health and Cornell Weill Medical College. Until now, little was known about the influence of a physician management company on prices. The findings are published in JAMA Internal Medicine.

“Physician management companies, many of which are backed by PE firms, have grown increasingly common in anesthesia. These companies manage the back-end administration of medical practices, including insurance contracting and billing, and also provide staffing and management services to health care facilities. The aim of our research was to study changes in prices paid to anesthesiologists and certified registered nurse anesthetists after a facility contracted with a PMC,” said Ambar La Forgia, PhD, assistant professor of health policy and management at Columbia Mailman School. “The paper considers the implications of corporate ownership in anesthesia for patients, practitioners and payers, and helps to inform the current policy debate around the corporate practice of medicine.”

The authors constructed a novel dataset identifying PMC contracts with hospital outpatient departments and ambulatory surgery centers from 2012-2017 and combined it with commercial claims data from three large national insurers in the Health Care Cost Institute database. Based on a sample of 2,255,933 privately-insured patients who received anesthesia services, the study found that allowed amounts paid to anesthesia practitioners increased by 16.5 percent or by $116.39 more in facilities that contracted with a PMC versus non-PMC facilities. Similarly, the unit price (allowed amounts standardized by procedure complexity and duration) increased by 19 percent or by $18.79 when facilities contracted with a PMC, suggesting that the price increases were not driven by changes in the types of procedures.

The study identified 22 PMCs as having provided anesthesia staffing and management services during the sample period. Half of these PMCs received funding from a PE firm. In subsample analyses, the authors found that PE-backed PMCs increased allowed amounts by 26 percent while PMCs without PE funding only increased allowed amounts by 13 percent.

“One way PMCs may command higher prices is by amassing market share and by developing better negotiating expertise,” noted La Forgia. “PE-backed PMCs may also have had stronger incentives to create short-term returns for investors relative to those without PE investments.”

PMCs may also gain negotiating leverage over insurers by threatening to move practitioners out-of-network. “Although we did not find evidence that practitioners moved out-of-network except for a modest increase in the year the contract started, the mere threat may be sufficient to influence negotiating dynamics between PMCs and insurance companies,“ observed La Forgia.

“Our research has important implications for payers, practitioners, patients, and policymakers. In recent legal disputes, insurance companies have argued that the prices they pay to PMC practitioners are too high, while PMCs have argued that large insurers do not adequately compensate practitioners. Either way, the proliferation of PMCs and PE firms in healthcare has raised concerns about increasing upward pressure on prices for in-network care, which can contribute to higher insurance premiums and higher patient cost-sharing.”

Co-authors are Amelia M. Bond, Robert Tyler Braun, Leah Z. Yao, Klaus Kjaer, Manyao Zhang, and Lawrence P. Casalino, Weill Cornell Medical College.

This research was supported by the Physicians Foundation Center for the Study of Physician Practice and Leadership at Weill Cornell Medical College, Arnold Ventures and the Commonwealth Fund. 

Columbia University Mailman School of Public Health
Founded in 1922, the Columbia University Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Columbia Mailman School is the fourth largest recipient of NIH grants among schools of public health. Its nearly 300 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change and health, and public health preparedness. It is a leader in public health education with more than 1,300 graduate students from 55 nations pursuing a variety of master’s and doctoral degree programs. The Columbia Mailman School is also home to numerous world-renowned research centers, including ICAP and the Center for Infection and Immunity. For more information, please visit www.mailman.columbia.edu.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.